Researchers develop ramanome-based metastatic assessment index to enhance cancer metastasis prediction
Researchers from Qingdao University and the Qingdao Institute of Bioenergy and Bioprocess Technology (QIBEBT) of the…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
ASH 2024: Daratumumab cuts risk of progression by half in smouldering multiple myeloma
Patients at high risk for developing multiple myeloma who received the drug daratumumab for up…
ASH 2024: Belantamab mafodotin shows significant OS benefit, reducing risk of death by 42% in multiple myeloma at or after first relapse
DREAMM-7 trial shows sustained overall survival benefit for the Blenrep (belantamab mandolin) combination versus the…
ASH 2024: Combination of two oral agents improves progression-free survival in previously untreated chronic lymphocytic leukaemia
Among patients with previously untreated chronic lymphocytic leukemia (CLL), those who received a combination regimen…
Common food poison toxin speeds colon cancer spread
A toxin in the bacteria that’s one of the most common causes of foodborne illness…
ASH 2024: Ketogenic diet boosts CAR T-Cell function for better tumour control
Findings from a series of studies conducted in mice, human tissues, and healthy volunteers suggest…
ASH 2024: Resistance training can reduce fatigue, pain in multiple myeloma patients
Researchers from Roswell Park Comprehensive Cancer Center, USA, presented compelling findings showcasing the significant benefits…
ASH 2024: High-fibre diet may slow disease progression in multiple myeloma
New data suggest that a plant-based diet rich in fibre could help to improve the…
SABCS 2024: PATINA clinical trial may represent a new standard of care for patients diagnosed with hormone receptor positive, HER-2 positive metastatic breast cancer
Researchers say that the results of the PATINA clinical trial may represent a new standard…
SABCS 2024: Camizestrant plus ribociclib improves PFS and responses in ER+/HER2– breast cancer
Results from the multicentre, first-in-human phase 1 SERENA-1 trial (NCT03616587) presented at the 2024 San…